HPD Research Day | February 16, 2018

65 important, but remains poorly acknowledged. Discussion. OSA may exacerbate coronary artery disease and poor quality of life. OSA is diagnosed by polysomnography and treatments include weight loss and continuous positive airway pressure (CPAP) devices. Screening guidelines and preventive treatment will be beneficial on the patient- level and on the national-level to reduce economic expense of OSA. Conclusion. The current obesity epidemic poses concerns for healthcare providers in terms of controlling common chronic illnesses such as hypertension and depression, all of which can result from or be exacerbated by untreated OSA. By advancing research through commencing a clinical study analyzing the use of inpatient CPAP device on patients with OSA, this may provide better understanding of how OSA impacts other physiologies and pathologies and divulge stronger comprehension to the mechanisms of OSA co-morbidities that we encounter every day. Atrium – Poster 73 12:15-1:15 p.m. Loss of CDKN1C in a Recurrent Atypical Teratoid/Rhabdoid Tumor Dustin Tran, OMS-I, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University Carl Koschmann, M.D., University of Michigan - Ann Arbor Introduction. We present the case of a child with recurrent atypical teratoid/rhabdoid tumor (AT/RT) who underwent clinically integrated molecular sequencing that revealed a novel loss-of-function mutation in CDKN1C alongside hallmark loss of SMARCB1. Case Presentation. A 6-week-old African-American female presented with respiratory distress, irritability, lethargy, and bulging fontanelle. MRI revealed a right posterior fossa mass with obstructive hydrocephalus. 8 months after gross tumor resection she returned with a recurrent right frontal lobe lesion and underwent palliative subtotal resection. Deviation From the Expected. In addition to biallelic loss of SMARCB1, a mutation in CDKN1C was reported and confirmed by immunohistochemistry and whole-exome and transcriptome sequencing in AT/RT. Discussion. Alisertib, an Aurora Kinase A (AURKA) inhibitor, was chosen for our patient due to previously published efficacy of the single-agent therapy in patients with recurrent AT/RT. Conclusion. Sequencing of the recurrent AT/RT revealed a novel mutation in CDKN1C could provide AT/RT new pathways for growth in addition to loss of AURKA regulation. Literature review strengthens evidence of a central upstream regulator, LIN28B, for both CDKN1C and AURKA. Further clarification of this oncogenic pathway in AT/RT should enable the development of improved targeted therapies in this patient population and provide perspective for future cancer research and therapies. Grants. The University of Michigan PEDS-MIONCOSEQ study was supported by grant 1UM1HG006508 from the National Institutes of Health Clinical Sequencing Exploratory Research Award (PI: Arul Chinnaiyan, Co-I: Rajen Mody). Carl Koschmann is supported by NIH/NINDS grant K08-NS099427-01. Atrium – Poster 74 12:15-1:15 p.m. Effects of BluTech Lenses on Melatonin, Sleep, Mood, and Neurobehavioral Performance Ryan-Quang Van, BS, OD-2, College of Optometry, Nova Southeastern University Ava K. Bittner, Ph.D., Associate Professor, College of Optometry, Nova Southeastern University Jaime Tartar, PhD, Associate Professor, College of Psychology, Nova Southeastern University Morgan Garman, College of Optometry, Nova Southeastern University Reaghan May, Nova Southeastern University Objective. We examined the effects of modifying short-wavelength blue light exposure on evening melatonin levels, sleep, mood and cognition. Background. Intrinsically photosensitive retinal ganglion cells respond to short- wavelength light and contribute to circadian rhythm entrainment. Evening light exposure can cause melatonin dysregulation, which is associated with impaired mood and performance. Methods. A randomized controlled trial with crossover-design evaluated BluTech Lenses (blue light filter) versus clear lenses with anti-reflective coating only (control). Twenty-four students wore these lenses after 6:00pm for five days (Mon.-Fri.). Actigraphy watches non-invasively recorded sleep patterns each night. On the fifth evening, saliva samples were collected to quantify melatonin levels, and self-reported mood and neurobehavioral performance were assessed with the NIH Toolbox Emotion and Cognition batteries, respectively. Results. A significant increase in melatonin levels was measured with BluTech Lenses compared to control (9.6 vs. 4.9; p=0.036). Sleep onset latency was slightly reduced with Blutech Lenses, but not significantly different between glasses (p=0.20). Pattern comparison was significantly